Steve Aselage

This profile gathers the share dealings of Steve Aselage across 3 companies, led by Biocryst Pharmaceuticals Inc, Travere Therapeutics, Inc. and Acer Therapeutics Inc. We count 20 filings; the first trade dates from 27 January 2016 and the latest from 12 June 2024.

Both buying and selling appear: 3 purchases worth €502k, against 3 sales worth €911k. Sales outweigh purchases by €409k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 9 share grants and 2 option exercises. 2024 to date brings 1 purchase and no sales.

Half of the purchases are above €15k and half below. 2 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The latest filing, published on 14 June 2024, reports a share grant in Biocryst Pharmaceuticals Inc. The last insider purchase was made public on 29 May 2024, 872 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.